Andy is an Operating Partner at DCVC Bio. Andy has spent much of his career at early-stage biotechnology companies, building teams and developing technologies from concept to commercial product. He currently works with a number of companies with technology platforms that are targeted towards solving some of the outstanding problems in gene and cell therapy. […]
Jenna Hebert is an Investment Director on the Venture Team at RA Capital Management. Jenna primary responsibility is to conduct due diligence on biotechnology companies at RA Capital and serve as a board director for Alchemab Therapeutics and a stealth RA Capital portfolio company. Prior to RA Capital, Jenna was an Analyst and Medical Writer at Costello Medical Consulting. Jenna has […]
Jane Osbourn is Alchemab’s Chief Executive Officer and provides overall leadership to the company. Prior to joining Alchemab, Jane served as Vice President of R&D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of antibody phage display technology, authored key publications and patents and contributed to the discovery and development […]
As Managing Partner of SV Health Investors, Kate Bingham co-leads SV’s biotech franchise, which has a long history of building companies developing transformational new medicines and bringing drugs from discovery to market. Kate’s investments, many of which are examples of SV’s company creation approach to biotech investing, include a wide range of drug discovery and […]
Kevin Lee is Chief Executive Officer of Bicycle Therapeutics and Non-Executive Director of Mestag and NodThera Ltd. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full […]